Sino Biopharmaceutical expanded its ties with AstraZeneca and GSK through new respiratory-focused deals. AstraZeneca will license rights to Sino’s investigational lung disease candidate TQC3721, with $200 million upfront and additional milestone payments up to $1.9 billion. In a separate agreement, Sino gains China ownership of GSK’s marketed respiratory medicines Trelegy and Anoro, positioning Sino as importer, promoter and distributor in China. The transaction is designed to deepen Sino’s commercial reach for GSK’s respiratory portfolio. The announcements land amid heightened scrutiny of U.S.-and-EU pharma-to-China alliances, and they reinforce AstraZeneca’s growing investment in respiratory R&D and manufacturing in China.